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Glioblastoma multiforme (GBM; grade IV astrocytoma) is the most
prevalent and aggressive form of primary brain cancer. A subpopu-
lation of multipotent cells termed GBM cancer stem cells (CSCs) play a
critical role in tumor initiation, tumor maintenance, metastasis, drug
resistance, and recurrence following surgery. Here we report the
identification of a small molecule, termed RIPGBM, from a cell-based
chemical screen that selectively induces apoptosis in multiple primary
patient-derived GBM CSC cultures. The cell type-dependent selectivity
of this compound appears to arise at least in part from redox-
dependent formation of a proapoptotic derivative, termed cRIPGBM,
in GBM CSCs. cRIPGBM induces caspase 1-dependent apoptosis by
binding to receptor-interacting protein kinase 2 (RIPK2) and acting as a
molecular switch, which reduces the formation of a prosurvival RIPK2/
TAK1 complex and increases the formation of a proapoptotic RIPK2/
caspase 1 complex. In an orthotopic intracranial GBM CSC tumor
xenograft mouse model, RIPGBM was found to significantly suppress
tumor formation in vivo. Our chemical genetics-based approach has
identified a drug candidate and a potential drug target that provide
an approach to the development of treatments for this devastating
disease.
glioblastoma | phenotypic drug screening | chemical genetics |
target identification | receptor-interacting protein kinase 2
Stem cell mechanisms have been established to play criticalroles in the development, progression, and recurrence of
multiple cancer types (1–5). One such case is the infiltrative brain
cancer glioblastoma multiforme (GBM). For recurrent GBM,
even with aggressive treatment, the median survival rate is pres-
ently 12–15 mo (6, 7). GBM cancer stem cells (CSCs) were among
the first cancer stem cell populations to be isolated and charac-
terized from solid tumors (8–11). These cells share features in
common with neural stem cells (NPCs), namely the expression of
NSC markers (e.g., Nestin and SOX2), the capacity for self-
renewal, and the ability to differentiate and give rise to cell
types of glial and neuronal lineages in response to inductive cues
(8, 9, 11, 12). The highly infiltrative nature of GBM tumors is
attributed to the ability of GBM CSCs to migrate within the brain,
a feature also shared with NSCs (13). Further, GBM CSCs are
thought to contribute to drug resistance (14, 15) and have even
been demonstrated to have the potential to give rise to endothelial
cells that enable tumor vascularization (16). Thus, efforts to de-
velop new therapeutic strategies for the treatment of GBM have
recently focused on targeting this stem cell population (17).
Here we have used an unbiased large-scale screening approach
to identify drug-like small molecules that induce apoptosis in
GBM CSCs in a cell type-selective manner. The use of expanded
populations of proliferative nonstem/multipotent GBM cells for
such screens is of limited utility, as such cell lines fail to re-
capitulate the in vitro and in vivo properties, including drug
sensitivity, of the original tumor (9, 18–22). In contrast, in vitro
and in vivo preclinical models using cultured human tumor-
derived GBM CSCs more accurately recapitulate the biology
of the disease (9, 15, 23–26). Under defined serum-free adher-
ent culture conditions, these patient-derived GBM CSCs can be
expanded as stable cell lines that retain their in vitro differen-
tiation potential, as well as their in vivo engraftment, tumor
formation, and migration potential (17). In the present study,
we have used patient-derived GBM CSC cultures to identify a
potential drug candidate for the treatment of this devastating
disease.
Results
RIPGBM Is a Selective Inducer of Apoptosis in GBM CSCs. We have
previously described an adapted system for the adherent in vitro
expansion of patient-derived GBM CSCs that was successfully
used to perform a kinomewide lentiviral RNAi screen in 384-well
assay format (24). Importantly, these primary cell lines retain
stem cell-like characteristics and differentiation properties, as
well as the ability to engraft and form tumors that recapitulate
Significance
We have completed a screen of ∼106 small molecules to iden-
tify compounds that induce cell death in multipotent glioblas-
toma multiforme (GBM) cancer stem cells (CSCs). This resulted
in the identification of a hit class (RIPGBM) that was found to
induce apoptosis in GBM CSCs in a cell type-selective manner.
Metabolite profiling experiments led to the identification of a
proapoptotic derivative of RIPGBM (cRIPGBM), which was
found to be selectively formed in GBM CSCs. Mechanistic
studies revealed that cRIPGBM induces apoptosis by binding to
receptor-interacting protein kinase 2 (RIPK2) in a mode that
results in the formation of a proapoptotic RIPK2/caspase 1
complex. In a physiologically relevant orthotopic intracranial
GBM CSC tumor xenograft mouse model, RIPGBMwas found to
significantly inhibit in vivo tumor formation.
Author contributions: N.C.L., H.W., P.S.M., and L.L.L. designed research; N.C.L., G.R.V.,
N.V., M.J.B., B.A.B., J.W.L., J.L.A., S.H.S., E.N.C., A.S., K.J., P.N.S., and L.L.L. performed
research; S.L.S. and H.W. contributed new reagents/analytic tools; N.C.L., P.G., H.W.,
P.G.S., P.S.M., and L.L.L. analyzed data; and N.C.L. and L.L.L. wrote the paper.
Reviewers: N.S.G., Harvard Medical School; and W.C.H., Dana–Farber Cancer Institute.
Conflict of interest statement: P.S.M. is cofounder of Pretzel Therapeutics, Inc. He has
equity and serves as a consultant for the company. P.S.M. also did a one-time consultation
for Abide Therapeutics, Inc.
This open access article is distributed under Creative Commons Attribution-NonCommercial-
NoDerivatives License 4.0 (CC BY-NC-ND).
1To whom correspondence may be addressed. Email: schultz@scripps.edu, pmischel@ucsd.
edu, or llairson@scripps.edu.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1816626116/-/DCSupplemental.
Published online March 7, 2019.









the highly heterogeneous and infiltrative characteristics of high-
grade gliomas in relevant rodent disease models (24). Here, we
used one of these GBM CSC lines, termed GBM-1, to establish a
robust 1,536-well format luciferase-based survival assay and
completed a large-scale screen of ∼106 drug-like small molecules
(1 μM) with the goal of identifying novel compounds that are
selectively toxic to chemoresistant GBM CSCs (Fig. 1A).
Confirmed primary hits (∼8,000, plate-based robust Z-score ≤−3)
were evaluated by using a laser scanning cytometer-based cell death
imaging assay (Acumen eX3; TTP Labtech; Fig. 1A). Selective cy-
totoxicity was determined by evaluating the primary hits at two
concentrations (5 μM and 1 μM), using a panel of two patient-
derived GBM CSC lines (GBM-1 and GBM-5, ref. 24) and 3
nondiseased cell types [primary human astrocytes, WA09 human ES
cell-derived NPCs, and primary human lung fibroblasts (HLFs)].
Compounds found to kill GBM CSC lines with greater than fivefold
toxicity index compared with control cell types were further char-
acterized. A caspase 3/7 activation assay (Caspase-Glo 3/7; Prom-
ega) was used to evaluate the mechanism of induced cell death. The
most potent and selective compound identified from these assays,
termed RIPGBM (Fig. 1A), was found to selectively induce apo-
ptosis in GBM CSC cell lines with an observed EC50 of ≤500 nM
and a selectivity index of at least fivefold compared with control cell
types (Fig. 1 B–D and SI Appendix, Table S1). For comparison, the
observed EC50 for the standard-of-care drug temozolomide (TMZ)
used to treat GBM is ≥20 μM for the same GBM CSC lines (SI
Appendix, Table S1). Moreover, human ES-derived NSCs are at
least twofold more sensitive to TMZ than GBMCSCs (SI Appendix,
Fig. S1). The latter observation is in agreement with published data
showing that GBM CSCs are resistant to chemotherapeutic agents
(27, 28). We confirmed the ability of RIPGBM to induce apoptosis
in GBM CSCs by immunofluorescent analysis using a cleaved cas-
pase 3-recognizing antibody (Fig. 1C).
RIPGBM Is Converted to an Apoptosis-Inducing Derivative Selectively
in GBM CSCs. Quinone-containing drugs represent a large and
diverse class of antitumor agents approved for clinical use. For
many of these drugs, cell type-selective reduction to reactive
hydroquinone species has been shown to play a key role in their
antitumor activity (29). As the naphthoquinone core of RIPGBM
is found in various substrates for quinone oxidoreductase enzymes
(e.g., NQO1), which generate hydroquinone or semihydroquinone
species and are frequently up-regulated in various cancer cell types
(30), we hypothesized that either of these events could lead to the
selective formation of a proapoptotic species in GBM CSCs. We
used an MS-based metabolite identification approach to evaluate
whether RIPGBM undergoes selective conversion to a +1 (i.e.,
semihydroquinone) or +2 (i.e., hydroquinone) species in GBM
CSCs. Cell pellets and growth media of GBM CSC and control
cell types were extracted following drug treatment and subjected
to quantitative high-resolution Orbitrap LC-MS analysis (Thermo
Fisher Scientific). The formation of +1 or +2 species was not
observed from samples derived from either cell type. However,
RIPGBM was found to undergo significant conversion to a −18
species, potentially corresponding to a dehydration event, in GBM
CSCs (∼50% in 24 h), and this conversion was found to occur
selectively in diseased cells (Fig. 2A). An accurate mass mea-
surement of 411.1506 m/z (SI Appendix, Fig. S2) and MS2 fragmen-
tation data (SI Appendix, Fig. S3) were consistent with the cyclized
imidazolium species, termed cRIPGBM, shown in Fig. 2B. In parallel
experiments, it was found that, whereas RIPGBM is relatively stable
in culture media (t1/2 > 4 d), addition of the reducing agent NaBH4
results in near-instantaneous formation of the −18 cRIPGBM species
(SI Appendix, Fig. S4). Presumably, reduction of the quinone moiety
makes the benzylic amine more nucleophilic, resulting in its addition
to the acetamido group and subsequent loss of water. The putative
cyclic derivative was synthesized and evaluated against a panel of
GBM CSCs and nondisease cell lines. The cyclized species
cRIPGBM was found to induce apoptosis in GBM CSCs with en-
hanced potency compared with the parent compound following 48
h of drug treatment (e.g., EC50 = 68 nM vs. 220 nM in GBM-1), but
with reduced selectivity compared with control cells (Fig. 2C and SI
Appendix, Table S1). As such, the mechanism by which RIPGBM
selectively induces cell death in GBM CSCs likely involves a redox-
dependent prodrug-like process involving cell type-dependent for-
mation of a proapoptotic species.
cRIPGBM Targets RIPK2 in GBM CSCs. Structure–activity relationship
studies revealed sites off the RIPGBM core tolerant of modifi-
cation. This information was used to design and synthesize
photoactivatable affinity probe (PAP) reagents. MS-based pro-
teomic target identification studies involving incubation and
photo-cross-linking with live GBM CSCs using cRIPGBM-PAP
(Fig. 2D), which retained activity (EC50) within fivefold of that of
Fig. 1. A cell-based phenotypic screening approach
identifies the small molecule RIPGBM, which induces
apoptosis in GBM CSCs in a cell type-selective man-
ner. (A) Schematic representation of the screening
approach used to identify molecules that selectively
induce apoptosis in GBM CSCs and structure of
RIPGBM. (B) Bright-field image of GBM CSCs (GBM-1)
or nondiseased human NPCs treated with RIPGBM
(1 μM) for 96 h. (C) Immunofluorescent analysis of
caspase 3 cleavage in GBM CSCs (GBM-1) following
treatment with RIPGBM (1 μM) for 24 h. (D) Cell sur-
vival curves for GBM CSCs (GBM-1), human NPCs, pri-
mary human astrocyte cells, and primary HLFs treated
with RIPGBM for 48 h. Values shown are mean ± SD.
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the parent molecule, resulted in the identification of receptor-
interacting serine-threonine kinase 2 (RIPK2) as a candidate
protein target for cRIPGBM (SI Appendix, Fig. S5). Based on its
known role in regulating apoptosis and the degree of identified
peptide coverage observed for this potential biomolecular target
(SI Appendix, Fig. S5B), RIPK2 was explored in detail to examine
its role in the mechanism of cRIPGBM-induced apoptosis.
In in vitro binding assays involving purified recombinant proteins,
cRIPGBM- PAP was observed to interact with full-length RIPK2
protein in a concentration-dependent manner at concentrations of
100 nM and greater (apparent Kd of ∼2.3 μM; SI Appendix, Fig. S5
C andD). A 25-fold molar excess of cRIPGBMwas found to inhibit
this interaction, demonstrating the specificity of this interaction
(Fig. 2E). Consistent with playing a relevant role in the induction of
apoptosis, RIPK2 consists of an N-terminal autophosphorylation
kinase domain and a C-terminal caspase 1 recruitment CARD
domain separated by a domain of unknown function (Fig. 2F) (31).
In vitro binding experiments suggest that cRIPGBM interacts with
the kinase domain of this protein (Fig. 2F). However, the com-
pound was not found to inhibit kinase activity at concentrations
lower than 10 μM in an RIPK2 enzymatic assay (SI Appendix, Fig.
S6). To further validate RIPK2 as the molecular target of
cRIPGBM in GBM CSCs, we measured compound-induced cyto-
toxicity and caspase activation in cells in which RIPK2 levels were
reduced by using shRNA. Consistent with the mechanistic relevance
of this target, as demonstrated by the observed reduction of
cRIPGBM-induced caspase 3/7 activation in GBM CSCs (Fig. 2G),
RIPK2 suppression resulted in a significant decrease in drug sen-
sitivity. The acyclic parent compound RIPGBM was not found to
interact with RIPK2 (Fig. 2E). These results suggest that it is the
Fig. 2. A metabolite of RIPGBM induces apoptosis in GBM CSCs by interacting with RIPK2. (A) Orbitrap MS-based metabolite identification studies in GBM-1
(GBM CSC) or primary HLF cells incubated with RIPGBM (1 μM) for 0, 12, 24, or 48 h. (B) Structure of the cyclized RIPGBM metabolite cRIPGBM generated in
GBM CSCs. (C) Cell survival curves for GBM CSCs (GBM-1), human NPCs, primary human astrocyte cells, and HLFs treated with cRIPGBM for 48 h. (D) Structure
of PAP reagent cRIPGBM-PAP. (E) In vitro binding of cRIPGBM-PAP to recombinant human full-length RIPK2 protein in the presence or absence of competition
using underivatized cRIPGBM or RIPGBM. (F) Domain structure of RIPK2 and in vitro binding of cRIPGBM-PAP to recombinant full-length, truncated kinase
domain, or truncated CARD domain human RIPK2 protein. (G) cRIPGBM-induced apoptosis in GBM-1 GBM CSCs following shRNA-mediated RIPK2 gene
knockdown. Values shown are mean ± SD (*P < 0.05, **P < 0.01, ***P < 0.005, and ****P < 0.001).









cyclized derivative cRIPGBM that is responsible for RIPK2-
dependent induction of apoptosis.
cRIPGBM Induces Caspase 1-Mediated Apoptosis. To elucidate the
downstream mechanism of action by which cRIPGBM induces ap-
optosis, we assessed caspase activation in GBM CSCs. Compound
treatment (250 nM) resulted in a time-dependent activation of cas-
pase 1, caspase 9, and caspase 7, as well as PARP cleavage (Fig. 3A),
providing further evidence that cRIPGBM induces cell death via an
apoptotic mechanism. Correspondingly, the pan-caspase inhibitor Z-
VAD-FMK significantly reduced compound-mediated GBM CSC
death (Fig. 3B). PARP cleavage occurred in a time-dependent
manner concomitant with the onset of DNA fragmentation as de-
termined by using a TUNEL assay (SI Appendix, Fig. S7). In addi-
tion, we established that caspase 1 activation is upstream of caspase
9, caspase 7, and PARP cleavage by observing that pretreatment
with the caspase 1 inhibitor Ac-YVAD-CHO effectively blocks
caspase 9 cleavage in cRIPGBM-treated GBM CSCs (Fig. 3C).
Ubiquitination is a known key modification that regulates the
ability of RIPK2 to act as a prosurvival or proapoptotic molecule (32,
33). Specifically, K63-ubiquitinated RIPK functions as a scaffold for
the assembly of protein complexes that activate prosurvival signal-
ing pathways (34–36). The E3 ubiquitin ligases cIAP1 and cIAP2
have been previously shown to interact with and promote RIPK2
ubiquitination in various cell lines (33, 37, 38). Coimmunoprecipita-
tion assays were used to determine if cRIPGBM treatment alters its
interaction with cIAP1 and/or cIAP2 in GBM CSCs. Compound
treatment reduced RIPK2 binding to cIAP1 (Fig. 3D) and signifi-
cantly reduced binding to cIAP2 in a dose-dependent manner (Fig.
3D), which suggests that cIAP1 and cIAP2 are endogenous regulators
of RIPK2 ubiquitination in GBM CSCs.
cRIPGBM Acts as a Molecular Switch That Modulates RIPK2 Binding
Partners. On the basis of these observations, as well as previously
established mechanisms that have been established for RIPK2 (34,
35), we hypothesized that cRIPGBM promotes cell death by
modulating RIPK2 ubiquitination status, which could impact its
interactions with a prosurvival molecule to favor its interaction with
a proapoptotic adaptor protein. To test this notion, we determined
if compound treatment alters RIPK2 binding partners by using
coimmunoprecipitation experiments. Previous studies have
established that K63-ubiquitinated RIPK2 associates with the
Fig. 3. cRIPGBM activates caspase 1-mediated apoptotic signaling in GBM CSCs bymodulating the interaction of RIPK2 with TAK1 and caspase 1. (A) Time-dependent
cRIPGBM (250 nM)-induced cleavage of caspase 1, caspase 9, caspase 7, and poly(ADP-ribose) polymerase (PARP) in GBM-1 GBM CSCs. (B) cRIPGBM-induced cell death
in GBM-1 GBM CSCs following treatment with the pan-caspase inhibitor Z-VAD (20 μM). (C) cRIPGBM-induced (250 nM) caspase 9 cleavage in GBM-1 GBM CSCs
following treatment with the caspase 1-selective inhibitor Ac-YVAD-CHO (20 μM). (D) Coimmunoprecipitation of cIAP1 and cIAP2 with anti-RIPK2 antibody in GBM-1
GBM CSCs following treatment with cRIPGBM. (E) Coimmunoprecipitation of TAK1 with anti-RIPK2 antibody in GBM-1 GBM CSCs following treatment with cRIPGBM
(250 nM). (F) Quantification of TAK1 levels coimmunoprecipitated by using an anti-RIPK2 antibody in GBM-1 GBM CSCs following treatment with cRIPGBM (250 nM).
(G) Coimmunoprecipitation of caspase 1 with anti-RIPK2 antibody in GBM-1 GBM CSCs following treatment with cRIPGBM (250 nM). (H) Quantification of caspase 1
levels coimmunoprecipitated by using an anti-RIPK2 antibody in GBM-1 GBM CSCs following treatment with cRIPGBM (250 nM). (I) Schematic representation of the
proposed mechanism of action for cRIPGBM-induced apoptosis in GBMB CSCs. Values shown are mean ± SD (*P < 0.05, **P < 0.01, ***P < 0.005, and ****P < 0.001).
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prosurvival TAK1 complex (34, 35). Consistently, TAK1 was
found to coimmunoprecipitate with RIPK2 under basal conditions
in GBM CSCs (Fig. 3E). In cRIPGBM-treated cells, the in-
teraction between RIPK2 and TAK1 was significantly decreased
(Fig. 3 E and F). Conversely, because cRIPGBM treatment in-
duces caspase 1-dependent cell death, we determined whether
drug treatment correlated with an increased association between
RIPK2 and caspase 1. Indeed, treatment with cRIPGBM for 6 h
was found to result in a significant enhancement of RIPK2–caspase
1 interaction (Fig. 3 G and H). Taken together, these data sug-
gest that cRIPGBM induces apoptosis in GBM CSCs by a
mechanism that involves its interaction with RIPK2 in a mode that
results in decreased association with TAK1 and increased associ-
ation with and activation of caspase 1, which can lead to down-
stream activation of a caspase 1-mediated apoptotic signaling
cascade (Fig. 3I). Additional future work will be required to de-
termine a detailed understanding of how cRIPGBM/RIPK2 in-
teraction impacts RIPK2 function in normal and disease cell types.
RIPGBM Inhibits Tumor Growth in a Patient-Derived GBM CSC Intracranial
Xenograft Model.The observed lack of brain exposure for cRIPGBM
following oral or i.p. dosing precluded characterization of its in vivo
activity using a physiologically relevant intracranial tumor model.
However, encouragingly, the parent acyclic cell type-selective
prodrug form of the molecule (RIPGBM), which would likely
be the preferred drug candidate based on its selectivity profile, was
found to have reasonable brain exposure properties following oral
administration (brain Cmax = 540 nM; brain t1/2 = 1.5 h; 20 mg/kg
orally; SI Appendix, Table S2). Further, in a 1-wk mouse toxicity
study, oral delivery of RIPGBM was well tolerated with no overt
toxicity observed at doses as high as 100 mg/kg twice per day based
on body weight loss (SI Appendix, Fig. S8) and terminal hema-
tology (SI Appendix, Tables S3 and S4), blood chemistry (SI Ap-
pendix, Table S5), and anatomical findings.
Given the selectivity and pharmacologic properties of RIPGBM,
we sought to assess its efficacy in vivo by using a clinically relevant,
patient-derived GBM intracranial xenograft model. In contrast to
non-CSC glioma cell lines, which fail to form tumors that re-
capitulate the heterogeneous highly infiltrative nature of the parent
tumor (9, 21), intracranial xenotransplantation of CSCs derived
from GBM tumors results in the formation of tumors that re-
capitulate the invasive nature of the human disease (8, 9, 24). A
highly aggressive GBM patient-derived line (GBM-39), which ro-
bustly recapitulates the heterogeneous and highly infiltrative nature
of GBM tumors in vivo (39, 40), was engineered to express the IR
fluorescent protein 720 (IRFP720) to allow noninvasive and
quantitative assessment of orthotopic tumor growth by fluorescence
molecular tomography (FMT) imaging. Oral administration of
RIPGBM (50 mg/kg orally twice daily) to mice bearing GBM39
IRFP720 intracranial xenografts resulted in a significant inhibition of
tumor growth, as monitored by FMT imaging (Fig. 4 A and B), which
was grossly associated with decreased tumor size, as assessed by H&E
staining (Fig. 4C). Taken together, these results demonstrate that oral
delivery of a well-tolerated dose of RIPGBM results in substantial
anti-GBM activity in vivo. Thus, with improvements in potency and
pharmacokinetic properties, this compound series has the potential to
provide a new therapeutic approach for patients with GBM.
Discussion
We have identified a small molecule, RIPGBM, that selectively
induces apoptosis in GBM CSCs in vitro and significantly de-
creases tumor size in vivo in a physiologically relevant, patient-
derived intracranial xenograft mouse model. The cell-type selec-
tivity of this prodrug molecule appears to be derived, at least in
part, from selective redox-dependent bioactivation in GBM CSCs,
which leads to the formation of a proapoptotic molecule termed
cRIPGBM, as well as sensitivity to RIPK2-induced apoptosis.
Additional target identification studies have yet to reveal a po-
tential activating enzyme for the RIPGBM prodrug molecule. As
such, it remains unclear if cyclization is dependent on a cell type-
specific enzymatic conversion or altered cellular redox potential.
Indeed, antioxidant response pathways (e.g., NRF2-dependent
pathways) are frequently found to be induced in diverse cancer
cell types as a result of oxidative stress and mutations within the
tumor microenvironment (41). Pharmacological data suggest that
the mechanism of action of cRIPGBM-induced apoptosis involves
its direct interaction with RIPK2. This results in decreased asso-
ciation with TAK1 and increased association with caspase 1,
leading to downstream activation of a caspase 1-mediated apo-
ptotic signaling cascade. Interestingly, RIPK2-dependent caspase
1-induced apoptosis has previously been demonstrated to play an
essential role in hypoxia and ischemia-induced neuronal cell death
(42), which is consistent with the ability of RIPK2 to act as a key
molecular switch that can control prosurvival vs. proapoptotic
signaling pathways in neural cell types including GBM CSCs.
Given the high rate of GBM tumor relapse following surgery,
which results from the therapeutic resistance of GBM CSCs, the
observed sensitivity of GBM CSCs to RIPK2-induced apoptosis
and the ability to control this molecular switch with an identified
small molecule has significant implications for the development of
new therapies for GBM. In theory, such a molecule could not only
decrease the rate of tumor regrowth, but also spare nontarget
cells, including normal neural cell populations, thus lowering the
side effects observed with standard-of-care treatments for GBM.
Fig. 4. RIPGBM reduces GBM tumor growth in an
orthotopic intracranial xenograft model. (A) GBM39
patient-derived neurosphere cells engineered to
stably express the IR protein 720 (IRFP 720) were
orthotopically injected into 5-wk-old nu/nu mice.
Mice were treated with vehicle or RIPGBM 50 mg/kg
orally twice daily (n = 8 for vehicle and n = 6 for
RIPGBM). (B) Representative FMT images of mice at
week 5. (C) Representative H&E stains of mouse
brains from mice at week 5. Values shown are
mean ± SD (*P < 0.05 and **P < 0.01).










Cell Culture. Deidentified tumor samples classified as GBM were obtained with
informed consent from patients undergoing surgery at Stanford Medical
Center in accordancewith the institutional reviewboards at StanfordUniversity
and The Scripps Research Institute. Specimen-derived cells were cultured at
37 °C and 5% CO2 conditions. GBM CSCs were maintained in Neurobasal
medium supplemented with N2, B27, and human basic FGF (20 ng/mL; Life
Technologies) and EGF (20 ng/mL; Life Technologies). WA09 human stem cell-
derived NPCs (Aruna Biomedical) were cultured following the manufacturer’s
instructions. HLFs (IMR-90; American Type Culture Collection CCL-186) were
cultured in MEM supplemented with 10% FBS and antibiotic/antimycotic
agents. Human astrocytes isolated from the cerebral cortex (no. 1800; ScienCell)
were cultured following the manufacturer’s instructions. Further details are
provided in SI Appendix, Supplemental Methods.
High-Throughput Screening. GBM-1 GBM CSCs were plated in complete GBM
media as described earlier at a density of 1,000 cells per well in 10 μL and
screened (1 μM, 0.1% DMSO) in 1,536-well plates coated with poly-D-lysine
(5 μg/mL; Sigma) and laminin (5 μg/mL; Life Technologies). Imaging-based
assays were performed by using an Acumen eX3 laser scanning cytometer
(TTP Labtech). Hit selection was performed by using plate-based analysis
(robust Z-scores <−3 for GBM CSCs and >−2 for control cell types). Further
details are provided in SI Appendix, Supplemental Methods.
Metabolite Identification Studies. GBM CSCs or control cells (200,000 per well)
were incubated with RIPGBM (1 μM) for 0–48 h and subjected to LC-MS
analysis as described in SI Appendix, Supplemental Methods.
cRIPGBM Protein Target Identification. GBM-1 GBM CSCs (∼106) were cultured
in 100-mm dishes and treated with 100 nM cRIPGBM-PAP for 1 h in the
presence or absence of 5 μM cRIPGBM. Bands selectively enriched in samples
lacking competition were evaluated by using a previously described method
(30). Further details are provided in SI Appendix, Supplemental Methods.
In Vivo Xenograft Animal Model. Five-week-old female athymic nu/nu mice
(Harlan Sprague–Dawley) were intracranially injected with 1 × 105 GBM39
IRFP720 cells in 5 μL of PBS solution as described previously (43). Tumor
growth was monitored by using an FMT 2500 Fluorescence Tomography
System (PerkinElmer) weekly. Mice were treated with vehicle [10% M-Pyrol,
10% ethanol/Cremophor (1:1, vol/vol), and 80% saline solution] or 50 mg/kg
of RIPGBM by oral gavage twice daily, 8 h apart, starting at day 7 post-
injection. All procedures were reviewed and approved by the institutional
animal use and care committee at the University of California, San Diego.
Further details are provided in SI Appendix, Supplemental Methods.
Synthesis. All chemicals and solvents were obtained from commercial suppliers
(Acros and Aldrich) and used without further purification. Unless otherwise indi-
cated, all reactionswere run under argongas. Anhydrous solventswere obtainedby
passage through an activated alumina column. The 1H and 13C NMR spectra were
recorded on a Bruker 400- and 500-MHz spectrometer. Chemical shifts are reported
relative to internal CDCl3 (Me4Si, δ 0.0), DMSO-d6 (Me4Si, δ 0.0), and CD3OD (Me4Si,
δ 0.0). Further details are provided in SI Appendix, Supplemental Methods.
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